Efficacy and safety of vixotrigine in idiopathic or diabetes-associated painful small fibre neuropathy (CONVEY): a phase 2 placebo-controlled enriched-enrolment randomised withdrawal studyResearch in context

Efficacy and safety of vixotrigine in idiopathic or diabetes-associated painful small fibre neuropathy (CONVEY): a phase 2 placebo-controlled enriched-enrolment randomised withdrawal studyResearch in context

Summary: Background: No pharmacological treatments are specifically indicated for painful small fibre neuropathy (SFN). CONVEY, a phase 2 enriched-enrolment study, evaluated the efficacy and safety of vixotrigine, a voltage- and use-dependent sodium channel blocker, in participants with idiopathic...

Full description

Bibliographic Details
Main Authors: Catharina G. Faber, Nadine Attal, Giuseppe Lauria, Robert H. Dworkin, Roy Freeman, Katherine T. Dawson, Helen Finnigan, Amirhossein Hajihosseini, Himanshu Naik, Michael Serenko, Christopher J. Morris, Mona Kotecha
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:EClinicalMedicine
Subjects:
Clinical trial
Diabetic peripheral neuropathy
Painful neuropathy
Sodium channel blocker
Nav inhibitor
Tolerability
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023001487

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023001487

Similar Items